Advanced search
Publication Cover
Cancer Management and Research Volume 10, 2018 - Issue
Submit an article Journal homepage
117
Views
24
CrossRef citations to date
0
Altmetric
Review

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

Jing-hua Pan1 Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China, [email protected]
,
Hong Zhou2 Department of Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
,
Sheng-bin Zhu1 Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China, [email protected]
,
Jin-lian Huang1 Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China, [email protected]
,
Xiao-xu Zhao1 Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China, [email protected]
,
Hui Ding1 Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China, [email protected]
&
Yun-long Pan1 Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China, [email protected]Correspondence[email protected]
 show all
Pages 2289-2301 | Published online: 01 Aug 2018

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Kristina Riegel & Krishnaraj Rajalingam. (2020) The non-linearity of RAF-MEK signaling in dendritic cells. Cell Cycle 19:18, pages 2249-2259.
Read now
Peng-Fei Wang, Han-Yue Qiu & Hai-Liang Zhu. (2019) A patent review of BRAF inhibitors: 2013-2018. Expert Opinion on Therapeutic Patents 29:8, pages 595-603.
Read now

Articles from other publishers (22)

Jae Min Ham, Myeongbin Kim, Taeho Kim, Seong Eon Ryu & Hwangseo Park. (2024) Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF. International Journal of Molecular Sciences 25:10, pages 5535.
Crossref
Adnane Aouidate. (2024) Exploring the chemical space of BRAF Inhibitors: A cheminformatic and Machine learning analysis. Journal of Molecular Liquids 401, pages 124705.
Crossref
Paola Roa, Nicole Virginia Bremer, Valentina Foglizzo & Emiliano Cocco. (2024) Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors. Cancers 16:6, pages 1215.
Crossref
Nishanth S. Sadagopan, Khizar R. Nandoliya, Mark W. Youngblood, Craig M. Horbinski, Jared T. Ahrendsen & Stephen T. Magill. (2023) A novel BRAF::PTPRN2 fusion in meningioma: a case report. Acta Neuropathologica Communications 11:1.
Crossref
Brittany Dewdney, Misty R. Jenkins, Sarah A. Best, Saskia Freytag, Krishneel Prasad, Jeff Holst, Raelene Endersby & Terrance G. Johns. (2023) From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress. Signal Transduction and Targeted Therapy 8:1.
Crossref
Ankit Kumar Singh, Pankaj Sonawane, Adarsh Kumar, Harshwardhan Singh, Vladislav Naumovich, Prateek Pathak, Maria Grishina, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas, Amita Verma & Pradeep Kumar. (2023) Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022. ACS Omega 8:31, pages 27819-27844.
Crossref
Hyun Kim, Jung Park, Sangjae Seo, Kwang-Hwi Cho, Mohammed Alanazi, Eun-Kyoung Bang, Gyochang Keum & Ashraf El-Damasy. (2023) Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity. International Journal of Molecular Sciences 24:4, pages 3216.
Crossref
Ankit Kumar Singh, Adarsh Kumar, Suresh Thareja & Pradeep Kumar. (2023) Current Insights into the Role of BRAF Inhibitors in Treatment of Melanoma. Anti-Cancer Agents in Medicinal Chemistry 23:3, pages 278-297.
Crossref
Guangchen Li, Yifu Cheng, Chi Han, Chun Song, Niu Huang & Yunfei Du. (2022) Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies. RSC Medicinal Chemistry 13:11, pages 1300-1321.
Crossref
Ankit Kumar Singh, Jurica Novak, Adarsh Kumar, Harshwardhan Singh, Suresh Thareja, Prateek Pathak, Maria Grishina, Amita Verma, Jagat Pal Yadav, Habibullah Khalilullah, Vikas Pathania, Hemraj Nandanwar, Mariusz Jaremko, Abdul-Hamid Emwas & Pradeep Kumar. (2022) Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine–sulfonamide hybrids as selective BRAF V600E inhibitors . RSC Advances 12:46, pages 30181-30200.
Crossref
Rahim Ullah, Qing Yin, Aidan H. Snell & Lixin Wan. (2022) RAF-MEK-ERK pathway in cancer evolution and treatment. Seminars in Cancer Biology 85, pages 123-154.
Crossref
Abdalla R. Mohamed & Ahmed M. El Kerdawy. (2022) A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry. Chemistry & Biodiversity 19:10.
Crossref
Daniel S. J. Miller, Sabine A. Voell, Izidor Sosič, Matic Proj, Olivia W. Rossanese, Gregor Schnakenburg, Michael Gütschow, Ian Collins & Christian Steinebach. (2022) Encoding BRAF inhibitor functions in protein degraders. RSC Medicinal Chemistry 13:6, pages 731-736.
Crossref
Victoria Bouchè, Giovanni Aldegheri, Carmine Antonio Donofrio, Antonio Fioravanti, Samuel Roberts-Thomson, Stephen B. Fox, Francesco Schettini & Daniele Generali. (2021) BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. Frontiers in Oncology 11.
Crossref
Qiu-Shi Zhuang, Xin-Bao Sun, Qing-Yun Chong, Arindam Banerjee, Min Zhang, Zheng-Sheng Wu, Tao Zhu, Vijay Pandey & Peter E. Lobie. (2021) ARTEMIN Promotes Oncogenicity and Resistance to 5-Fluorouracil in Colorectal Carcinoma by p44/42 MAPK Dependent Expression of CDH2. Frontiers in Oncology 11.
Crossref
Helene Bellio, Jean David Fumet & Francois Ghiringhelli. (2021) Targeting BRAF and RAS in Colorectal Cancer. Cancers 13:9, pages 2201.
Crossref
David G. Covell. (2021) Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action. PLOS ONE 16:4, pages e0243336.
Crossref
Abdalla R. Mohamed, Ahmed M. El Kerdawy, Riham F. George, Hanan H. Georgey & Nagwa M. Abdel Gawad. (2021) Design, synthesis and in silico insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities. Bioorganic Chemistry 107, pages 104569.
Crossref
Juliana F. Vilachã, Sarah C. Mitchel, Muluembet Z. Akele, Stephen Evans & Matthew R. Groves. (2020) Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. Crystals 10:9, pages 725.
Crossref
Ana Bela Sarmento-Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth & Ioannis P. Trougakos. (2019) The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 47, pages 100646.
Crossref
Jiangning Li & Xiaofeng Li. (2019) Encorafenib inhibits migration, induces cell cycle arrest and apoptosis in colorectal cancer cells. Molecular and Cellular Biochemistry 459:1-2, pages 113-120.
Crossref
Michel Ducreux, Ali Chamseddine, Pierre Laurent-Puig, Cristina Smolenschi, Antoine Hollebecque, Peggy Dartigues, Emmanuelle Samallin, Valérie Boige, David Malka & Maximiliano Gelli. (2019) Molecular targeted therapy of BRAF -mutant colorectal cancer . Therapeutic Advances in Medical Oncology 11, pages 175883591985649.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.